Abstract:Multifunctional platinumIV anticancer prodrugs have the potential to enrich the anticancer properties and overcome the clinical problems of drug resistance and side effects of platinumII anticancer agents. Herein, we develop dual and triple action platinumIV complexes with targeted and biological active functionalities. One complex (PFL) that consists of cisplatin, tegafur, and lonidamine exhibits strong cytotoxicity against triple negative breast cancer (TNBC) cells. Cellular uptake and distribution studies reveal that PFL mainly accumulates in mitochondria. As a result, PFL disrupts the mitochondrial ultrastructure and induces significant alterations in the mitochondrial membrane potential, which further leads to an increase in production of reactive oxygen species (ROS) and a decrease in ATP synthesis in MDA-MB-231 TNBCs. Western blot analysis reveals the formation of ternary complex of thymidylate synthase, which shows the intracellular conversion of tegafur into 5-FU after its release from PFL. Furthermore, treatment with PFL impairs the mitochondrial function, leading to the inhibition of glycolysis and mitochondrial respiration and induction of apoptosis through the mitochondrial pathway. The RNA-sequencing experiment shows that PFL can perturb the pathways involved in DNA synthesis, DNA damage, metabolism, and transcriptional activity. These findings demonstrate that PFL intervenes in several cellular processes including DNA damage, thymidylate synthase inhibition, and perturbation of the mitochondrial bioenergetics to kill the cancer cells. The results highlight the significance of a triple-action prodrug for efficient anticancer therapy for TNBCs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.inorgchem.0c01736?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.inorgchem.0c01736</a>.Supporting experimental methods; characterization of the complexes; stability data; reduction of the complexes by AA; Hoechst staining; ATP assay and RNA-seq data (<a class="ext-link" href="/doi/suppl/10.1021/acs.inorgchem.0c01736/suppl_file/ic0c01736_si_001.pdf">PDF</a>)List of genes that are up-regulated or down-regulated (<a class="ext-link" href="/doi/suppl/10.1021/acs.inorgchem.0c01736/suppl_file/ic0c01736_si_002.xlsx">XLSX</a>)List of transcription factor (TF) genes that are up-regulated or down-regulated (<a class="ext-link" href="/doi/suppl/10.1021/acs.inorgchem.0c01736/suppl_file/ic0c01736_si_003.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Development of a novel thymidylate synthase (TS) inhibitor capable of up-regulating P53 expression and inhibiting angiogenesis in NSCLC

Discovery of novel thymidylate synthase (TS) inhibitors that influence cancer angiogenesis and metabolic reprogramming in NSCLC cells

Novel 2-Phenyl-3-(pyridin-2-yl) Thiazolidin-4-one Derivatives As Potent Inhibitors for Proliferation of Osteosarcoma Cells in Vitro and in Vivo

Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations

Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions

Design, synthesis, and biological evaluation of novel 5,7,4'-trimethoxyflavone sulfonamide-based derivatives as highly potent inhibitors of LRPPRC/STAT3/CDK1

Synthesis and Anticancer Evaluation of Benzylated Indole Based Alkyl‐Substituted Pyrido[2,3‐d]Pyrimidines Targeting Thymidylate Synthase

Novel 1,3,4-Oxadiazole Thioether Derivatives Targeting Thymidylate Synthase As Dual Anticancer/antimicrobial Agents.

Standing the test of time: targeting thymidylate biosynthesis in cancer therapy

Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment

Specific Growth Inhibition by Alteration of Metabolic Pathway Using Chinese Herbal Medicine in Tyrosine Kinase Inhibitor Resistant Non-Small Cell Lung Cancer

Design, synthesis and in vitro anticancer research of novel tetrandrine and fangchinoline derivatives

Design, Synthesis and Biological Evaluation of N-phenylsulfonylnicotinamide Derivatives As Novel Antitumor Inhibitors.

Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non-small cell lung cancer

Discovery of 5-(Methylthio)pyrimidine Derivatives As L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.

Novel sulfonyl-substituted tetrandrine derivatives for colon cancer treatment by inducing mitochondrial apoptosis and inhibiting PI3K/AKT/mTOR pathway

Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells

In Vivo Validation of Novel P53-Independent Therapeutic Modalities for Small Cell Lung Cancer (SCLC).

Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer

Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo

An insight into thymidylate synthase inhibitor as anticancer agents: an explicative review